A new strategy for selective targeting of progesterone receptor with passive antagonists

Molecular Endocrinology

Volumn 27, Issue 6, 2013, Pages 909-924

  Khan, Junaid A ^a   Tikad, Abdellatif ^b,c   Fay, Michel ^d   Hamze, Abdallah ^b,c   Fagart, Jérôme ^a   Chabbert Buffet, Nathalie ^e,f   Meduri, Geri ^a   Amazit, Larbi ^a,g   Brion, Jean Daniel ^a   Alami, Mouad ^b,c   Lombès, Marc ^a,b   Loosfelt, Hugues ^a   Rafestin Oblin, Marie Edith ^d  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c BioCIS UMR 8076 ^*

^d CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^e HÔPITAL TENON   (France)

^f CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^g Univ Paris Sud   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGESTAGEN; HYDROGEN; NUCLEAR RECEPTOR COREPRESSOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR; THYROID HORMONE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYDROGEN BOND; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS, HORMONAL; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HEK293 CELLS; HOMOSTEROIDS; HUMANS; MODELS, MOLECULAR; NEOPLASMS, HORMONE-DEPENDENT; PROTEIN BINDING; PROTEOLYSIS; RECEPTORS, PROGESTERONE; STEROIDS; TRANSCRIPTION FACTORS;

EID: 84877889736     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1328     Document Type: Article

References (70)

1. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia. 2002;7:3-15.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
3. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
4. Bakken K, Fournier A, Lund E, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;128:144-156.
5. Liang Y, Benakanakere I, Besch-Williford C, Hyder RS, Ellersieck MR, Hyder SM. Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice. Menopause. 2010;17:1040-1047.
6. Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab. 2008;93: 3295-3298.
7. Lanari C, Lamb CA, Fabris VT, et al. TheMPAmouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer. 2009;16:333-350.
8. Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468:103-107.
9. Joshi PA, Jackson HW, Beristain AG, et al. Progesterone induces adult mammary stem cell expansion. Nature. 2010;465:803-807.
10. Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468:98-102.
11. Klijn JG, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 2000;65:825-830.
12. Vanzulli SI, Soldati R, Meiss R, Colombo L, Molinolo AA, Lanari C. Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression. Carcinogenesis. 2005;26:1055-1063.
13. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science. 2006;314:1467-1470.
14. Luo X, Yin P, Coon V JS, Cheng YH, Wiehle RD, Bulun SE. The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Fertil Steril. 2010;93:2668-2673.
15. Busia L, Faus H, Hoffmann J, Haendler B. The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression. Mol Cell Endocrinol. 2011;333:37-46.
16. Wiehle R, Lantvit D, Yamada T, Christov K. CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis. Cancer Prev Res (Phila). 2011;4:414-424.
17. Stanczyk FZ. All progestins are not created equal. Steroids. 2003; 68:879-890.
18. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas. 2003;46(Suppl 1):S7-S16.
19. Sitruk-Ware R, Bossemeyer R, Bouchard P. Preclinical and clinical properties of trimegestone: a potent and selective progestin. Gynecol Endocrinol. 2007;23:310-319.
20. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2008;61:151-157.
21. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/ thyroid receptor superfamily members. Annu Rev Biochem. 1994;63:451-486.
22. Georgiakaki M, Chabbert-Buffet N, Dasen B, et al. Ligand-controlled interaction of histone acetyltransferase binding to ORC-1 (HBO1) with the N-terminal transactivating domain of progesterone receptor induces steroid receptor coactivator 1-dependent coactivation of transcription. Mol Endocrinol. 2006;20:2122-2140.
23. Kemppainen JA, Lane MV, Sar M, Wilson EM. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem. 1992;267:968-974.
24. Lu NZ, Wardell SE, Burnstein KL, et al. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev. 2006;58: 782-797.
25. Madauss KP, Grygielko ET, Deng SJ, et al. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol. 2007;21:1066-1081.
26. Madauss KP, Stewart EL, Williams SP. The evolution of progesterone receptor ligands. Med Res Rev. 2007;27:374-400.
27. Spitz IM. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids. 2003;68:981-993.
28. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005;11:293-307.
29. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev. 2005;26:423-438.
30. Wardell SE, Edwards DP. Mechanisms controlling agonist and antagonist potential of selective progesterone receptor modulators (SPRMs). Semin Reprod Med. 2005;23:9-21.
31. Liu Z, Auboeuf D, Wong J, et al. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci U S A. 2002;99:7940-7944.
32. Chabbert-Buffet N, Pintiaux A, Bouchard P. The immninent dawn of SPRMs in obstetrics and gynecology. Mol Cell Endocrinol. 2012; 358:232-243.
33. Fagart J, Wurtz JM, Souque A, Hellal-Levy C, Moras D, Rafestin-Oblin ME. Antagonism in the human mineralocorticoid receptor. EMBO J. 1998;17:3317-3325.
34. Shiau AK, Barstad D, Radek JT, et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol. 2002;9:359-364.
35. Söderholm AA, Lehtovuori PT, Nyrönen TH. Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain. Journal of medicinal chemistry. 2005;48:917-925.
36. Williams SP, Sigler PB. Atomic structure of progesterone complexed with its receptor. Nature. 1998;393:392-396.
37. Madauss KP, Deng SJ, Austin RJ, et al. Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004;47:3381-3387.
38. Petit-Topin I, Turque N, Fagart J, et al. Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins. Mol Pharmacol. 2009;75:1317-1324.
39. Raaijmakers HC, Versteegh JE, Uitdehaag JC. The x-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation. J Biol Chem. 2009;284:19572-19579.
40. Monsalve LN, Machado Rada MY, Ghini AA, Baldessari A. An efficient enzymatic preparation of 20-pregnane succinates: chemoenzymatic synthesis of 20β-hemisuccinyloxy-5_H-pregnan-3- one. Tetrahedron. 2008;64:1721-1730.
41. Khan JA, Amazit L, Bellance C, Guiochon-Mantel A, Lombès M, Loosfelt H. p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization. Mol Endocrinol. 2011;25:1710-1724.
42. Smid-Koopman E, Blok LJ, Kühne LC, et al. Distinct functional differences of human progesterone receptors A and B on gene expression and growth regulation in two endometrial carcinoma cell lines. J Soc Gynecol Investig. 2003;10:49-57.
43. Hellal-Levy C, Couette B, Fagart J, Souque A, Gomez-Sanchez C, Rafestin-Oblin M. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Lett. 1999;464:9-13.
44. Fagart J, Huyet J, Pinon GM, Rochel M, Mayer C, Rafestin-Oblin ME. Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nat Struct Mol Biol. 2005;12:554-555.
45. Amazit L, Alj Y, Tyagi RK, et al. Subcellular localization and mechanisms of nucleocytoplasmic trafficking of steroid receptor coactivator- 1. J Biol Chem. 2003;278:32195-32203.
46. Cullingford TE, Pollard JW. RU 486 completely inhibits the action of progesterone on cell proliferation in the mouse uterus. J Reprod Fertil. 1988;83:909-914.
47. Bellance C, Khan JA, Meduri G, Guiochon-Mantel A, Lombes M, Loosfelt H. Progesterone receptor isoforms PRA and PRB differentially contribute to breast cancer cell migration through interaction with focal adhesion kinase complexes [published online March 13, 2013]. Mol Biol Cell. doi:10.1091/mbc.E12-11-0807.
48. Lombes M, Binart N, Oblin ME, Joulin V, Baulieu EE. Characterization of the interaction of the human mineralocorticosteroid receptor with hormone response elements. Biochem J. 1993;292(Pt 2):577-583.
49. Hubler TR, Scammell JG. Intronic hormone response elements mediate regulation of FKBP5 by progestins and glucocorticoids. Cell Stress Chaperones. 2004;9:243-252.
50. Kleywegt GJ, Jones TA. Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallogr D Biol Crystallogr. 1994;50:178-185.
51. Shen T, Horwitz KB, Lange CA. Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol. 2001;21:6122-6131.
52. Zhang Y, Beck CA, Poletti A, Edwards DP, Weigel NL. Identification of a group of Ser-Pro motif hormone-inducible phosphoryladoition sites in the human progesterone receptor. Mol Endocrinol. 1995;9:1029-1040.
53. Rosenfeld MG, Glass CK. Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem. 2001;276:36865-36868.
54. Wang D, Wang Q, Awasthi S, Simons SS Jr. Amino-terminal domain of TIF2 is involved in competing for corepressor binding to glucocorticoid and progesterone receptors. Biochemistry 2007;46: 8036-8049.
55. Nagy L, Schwabe JW. Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci. 2004;29:317-324.
56. Schoch GA, D'Arcy B, Stihle M, et al. Molecular switch in the glucocorticoid receptor: active and passive antagonist conformations. J Mol Biol. 2010;395:568-577.
57. Lusher SJ, Raaijmakers HC, Vu-Pham D, et al. Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators. J Biol Chem. 2011;286:35079-35086.
58. Lusher SJ, Raaijmakers HC, Vu-Pham D, et al. X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11β-substituted steroids. J Biol Chem. 2012;287:20333-20343.
59. Matias PM, Donner P, Coelho R, et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem. 2000;275:26164-26171.
60. Bledsoe RK, Montana VG, Stanley TB, et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell. 2002;110:93-105.
61. Bledsoe RK, Madauss KP, Holt JA, et al. A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J Biol Chem. 2005;280:31283-31293.
62. Thompson SK, Washburn DG, Frazee JS, et al. Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists. Bioorg Med Chem Lett. 2009;19:4777-4780.
63. Kallander LS, Washburn DG, Hoang TH, et al. Improving the developability profile of pyrrolidine progesterone receptor partial agonists. Bioorg Med Chem Lett. 2010;20:371-374.
64. Dressing GE, Hagan CR, Knutson TP, Daniel AR, Lange CA. Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocr Relat Cancer. 2009;16:351-361.
65. Knutson TP, Daniel AR, Fan D, et al. Phosphorylated and sumoylation- deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res. 2012; 14:R95.
66. Guiochon-Mantel A, Lescop P, Christin-Maitre S, Loosfelt H, Perrot- Applanat M, Milgrom E. Nucleocytoplasmic shuttling of the progesterone receptor. EMBO J. 1991;10:3851-3859.
67. Presman DM, Alvarez LD, Levi V, et al. A Insights on glucocorticoid receptor activity modulation through the binding of rigid steroids. PLoS One. 2010;5:e13279.
68. Fejes-Tóth G, Pearce D, Náray-Fejes-Tóth A. Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. Proc Natl Acad Sci U S A. 1998;95:2973-2978.
69. Khan JA, Bellance C, Guiochon-Mantel A, Lombes M, Loosfelt H. Differential regulation of breast cancer-associated genes by progesterone receptor isoforms PRA and PRB in a new bi-inducible breast cancer cell line. PLoS One. 2012;7:e45993.
70. Lanari C, Wargon V, Rojas P, Molinolo AA. Antiprogestins in breast cancer treatment: are we ready? Endocr Relat Cancer. 2012;19:R35-R50.